The semen-derived enhancer of viral infection (SEVI) is a positively charged amyloid fibril that is derived from a self-assembling proteolytic cleavage fragment of prostatic acid phosphatase (PAP 248-286 ). SEVI efficiently facilitates HIV-1 infection in vitro, but its normal physiologic function remains unknown. In light of the fact that other amyloidogenic peptides have been shown to possess direct antibacterial activity, we investigated whether SEVI could inhibit bacterial growth. Neither SEVI fibrils nor the unassembled PAP 248-286 peptide had significant direct antibacterial activity in vitro. However, SEVI fibrils bound to both Grampositive (Staphylococcus aureus) and Gram-negative (Escherichia coli and Neisseria gonorrhoeae) bacteria, in a charge-dependent fashion. Furthermore, SEVI fibrils but not the monomeric PAP 248-286 peptide promoted bacterial aggregation and enhanced the phagocytosis of bacteria by primary human macrophages. SEVI also enhanced binding of bacteria to macrophages and the subsequent release of bacterially induced proinflammatory cytokines (tumor necrosis factor alpha [TNF-␣], interleukin-6 [IL-6], and IL-1␤). Finally, SEVI fibrils inhibited murine vaginal colonization with Neisseria gonorrhoeae. These findings demonstrate that SEVI has indirect antimicrobial activity and that this activity is dependent on both the cationic charge and the fibrillar nature of SEVI.
H uman semen has recently been shown to contain cationic amyloid fibrils (1-3), the best characterized of which is the semen-derived enhancer of viral infection (SEVI) (3) . SEVI is formed from a self-assembling peptide cleavage product of prostatic acid phosphatase (PAP ) and has been shown to facilitate HIV-1 infection of cultured cells (3) . It is distinguished from other amyloids because of its strong positive charge, as well as the fact that it does not appear to be associated with disease (3) (4) (5) . However, SEVI's normal physiologic function remains unknown.
Interestingly, other amyloidogenic peptides such as amyloid-␤ and protegrin-1 (6) (7) (8) have been shown to have bactericidal properties, which are thought to be mediated via a channel-forming mechanism (9) . Amyloid-forming peptides have also been shown to mediate antimicrobial effects by binding and sequestering bacteria. For example, eosinophil cationic peptide (ECP) has been shown to form amyloid-like structures that mediate bacterial aggregation (10) . The antimicrobial effects of such aggregation have been convincingly demonstrated for human ␣-defensin 6, which has been shown to protect the gastrointestinal mucosa of transgenic mice from infection with pathogenic bacteria, by self-assembling into amyloid-like structures ("nanonets") that entrap bacteria (11) .
We therefore reasoned that SEVI fibrils may also have antibacterial activity and that they may contribute to the well-documented antimicrobial effects of human semen (12) , which contains multiple antimicrobial polypeptides, including defensins, semenogelin-derived peptides, and hCAP-18, the precursor to the human antimicrobial cathelicidin protein, LL-37 (12) (13) (14) (15) (16) . Like LL-37, SEVI is highly cationic-a property that differentiates it from other amyloid-forming peptides. This suggested to us that SEVI and other cationic amyloid fibrils might have unique antimicrobial or immune modulatory properties and that these fibrils might bind to bacterial pathogens via electrostatic interactions. Indeed, most bacteria have an anionic surface charge at neutral pH (17) , with an isoelectric point that lies in the range of pH 2 to 5, including both Gram-positive organisms (e.g., Staphylococcus aureus with a pI of 3.4, cited in reference 18) and Gram-negative organisms (e.g., Escherichia coli with a pI of 2.5, cited in reference 10, and Neisseria gonorrhoeae with a pI of 5.3, cited in reference 19) .
Consistent with our prediction, we found that SEVI bound to both Gram-positive (S. aureus) and Gram-negative (E. coli and N. gonorrhoeae) bacteria. In contrast, amyloid fibrils formed from a noncationic derivative of the PAP 248-286 peptide, in which all arginine and lysine residues were replaced with alanine (designated SEVIala [20] ), failed to bind bacteria. SEVI fibrils also promoted bacterial aggregation and enhanced the phagocytosis of bacteria by primary human monocyte-derived macrophages (MDM), whereas the monomeric PAP 248-286 peptide and the SEVIala mutant fibrils had no such effect. In addition, SEVI increased the efficiency of bacterial binding to human MDM and the subsequent release of bacterially induced proinflammatory cytokines (tumor necrosis factor alpha [TNF-␣], interleukin-6 [IL-6], and IL-1␤). Finally, SEVI fibrils reduced murine vaginal infection with N. gonorrhoeae. These findings demonstrate that SEVI has both immunomodulatory and indirect antimicrobial activity and that these activities are dependent on both the cationic charge and the fibrillar nature of the peptide.
MATERIALS AND METHODS
Bacterial strains. The following bacterial strains were used in these experiments: E. coli CFT073 (K-12 [ATCC]); S. aureus UAMS1 (Mark Smeltzer, University of Arkansas Medical School), S. aureus KLA16 (UAMS1 ⌬spa) and its genetically complemented, protein A-positive derivative (21) , and S. aureus Wood 46 (ATCC); and N. gonorrhoeae FA1090 (ATCC).
SEVI binding assay. Fluorescent bacterial particles were used to examine bacterial binding to SEVI. For S. aureus and E. coli, we purchased fluorescein isothiocyanate (FITC)-conjugated bacterial particles (Invitrogen). No analogous reagent was available for N. gonorrhoeae, so we labeled this organism using carboxyfluorescein succinimidyl ester (CFSE; Invitrogen). Fluorescently labeled bacteria were resuspended in phosphatebuffered saline (PBS) at a concentration of 3 ϫ 10 8 particles/ml and incubated at 37°C with 35 g/ml of biotinylated SEVI fibrils (formed from a biotinylated derivative of the PAP 248-286 peptide [22] ). In control experiments, bacteria were incubated with biotinylated noncationic fibrils formed from a mutant derivative of the PAP 248-286 peptide, in which all arginine and lysine residues were replaced with alanine (this peptide is known as SEVIala) (20) . After 1 h of incubation at 37°C, antibiotin-conjugated magnetically activated cell sorting (MACS) beads (Miltenyi Biotec) in PBS containing 2.5% bovine serum albumin (BSA) were added to the mixture, which was placed on ice for 20 min to allow binding. The entire sample was then run on a magnetic separation column. The flowthrough was discarded, and the bound material was released from the column, placed into 96-well plates, and pelleted at 900 ϫ g for 12 min prior to being resuspended in PBS for fluorescence quantification (485-nm excitation wavelength and 535-nm emission wavelength) in a Beckman Coulter DTX 880 plate reader.
Analysis of bacterial sedimentation. SEVI-mediated aggregation of bacterial particles was assessed by sedimentation using bacterial particles labeled with the fluorescent dye pHrodo. This dye was chosen because the particles were readily visible under room light even at neutral pH, allowing us to easily visualize sedimentation. Fluorescent S. aureus and E. coli bacteria were mixed with SEVI, SEVIala (40 g/ml), or PBS alone. After vortexing, the samples were transferred to Wintrobe tubes (Fisher Scientific), incubated at 37°C for 1 h, and then photographed to document bacterial sedimentation.
TEM. For transmission electron microscopy (TEM) visualization, SEVI was diluted to 35 g/ml in 15 l of PBS. S. aureus particles (2 ϫ 10 7 ) were then added and incubated at 37°C for 1 h. An equal volume of 2.5% phosphate-buffered glutaraldehyde was then added, and the solution was incubated for 30 min, after which 1 drop of the fixed sample was placed on a carbon film mesh nickel grid (Electron Microscopy Sciences) and air dried. Samples were stained with 2.0% phosphotungstic acid (pH 6.5) (PTA) and imaged on an H7650 Hitachi transmission electron microscope (Hitachi, Japan).
Antimicrobial assays. Direct antimicrobial activity of SEVI fibrils and the monomeric PAP248-286 peptide was determined by microdilution MIC testing. Inocula containing ϳ1ϫ 10 5 mid-exponential-phase cells were dispensed into the wells of polypropylene 96-well plates (BD, San Jose, CA) containing seven 2-fold dilutions of test peptide in growth medium. Plates were then incubated overnight (12 to 18 h) at 37°C, and the MIC value was determined as the lowest concentration of peptide that inhibited bacterial growth, as measured by the unaided eye. In the case of N. gonorrhoeae, we performed a pseudo-MBC (minimal bactericidal concentration) assay. To do this, bacteria were incubated aerobically in supplemented GCP medium (23) for 2 h and then plated onto GC agar and incubated overnight at 37°C in the presence of 5% CO 2 . Apparent peptide MBC values were recorded as the lowest peptide concentration able to reduce cell growth at least 2-fold in the CFU assay.
Human MDM. Peripheral blood mononuclear cells were isolated from buffy coats of healthy human donors by Ficoll density gradient centrifugation, and CD14 ϩ monocytes were purified by positive selection using anti-CD14-conjugated magnetic beads (Miltenyi Biotec). Cells were suspended at 1.0 ϫ 10 6 cells/ml in RPMI medium containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 2% glutamine, and 5 ng/ml human granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech) added on day 0 and day 3. On day 5, GM-CSF-containing medium was removed, and cells were cultured until day 6 or 7 in RPMI medium containing 10% FBS.
Neutrophil isolation. Peripheral blood was collected into plasma separator blood tubes, and polymorphonuclear leukocytes (PMNs) were purified with 1-Step Polymorphs (Accurate Chemical and Science Corp.). The PMN layer was removed, washed with Hanks balanced salt solution (HBSS) (without Ca 2ϩ or Mg 2ϩ ) plus 0.1% BSA, and red blood cells were lysed. PMNs were then counted and plated in 12-well tissue culture plates at 1 ϫ 10 6 cells/well in 1 ml of PBS. After 1 h, the PMNs were used for the gentamicin protection assay as outlined below.
Phagocytosis assays using killed bacteria (flow cytometric assay). Phagocytosis assays were conducted using pHrodo-labeled, killed bacteria (BioParticles; Invitrogen). This dye fluoresces brightly under low-pH conditions and thus allows one to conveniently differentiate phagocytosed bioparticles (which fluoresce brightly in the low-pH environment of the endosome) from bioparticles that remain bound to the cell surface (which do not fluoresce brightly). Briefly, pHrodo-labeled bacteria were resuspended in PBS at a concentration of 2 mg/ml and then mixed with SEVI, SEVIala, monomeric PAP 248-286 peptides, or PBS alone. The resulting mixtures were vortexed and incubated in a water bath at 37°C for 1 h, after which 20 to 35 l of the suspension was added to human MDM, to achieve a final concentration of between 20 and 40 g/ml of SEVI. MDM and the fibril-bioparticle mixture were incubated for 1 h at 37°C. In control experiments, MDM were preincubated with cytochalasin-D (SigmaAldrich) at a concentration of 2 g/ml for 30 min, prior to the addition of the fibril-bacterial mixture. After incubation with the fluorescent bacteria, MDM were harvested using a 1% trypsin solution and resuspended in PBS containing 2% FBS for flow cytometric analysis on a FACSCalibur (BD) cytometer.
Phagocytosis assays using live bacteria (gentamicin protection assay). MDM were prepared as described above. Mid-log-phase bacteria were preincubated in PBS in the presence or absence of SEVI (35 g/ml) and then added to cells. After 1 h, inocula were removed and the MDM treated with 200 g/ml gentamicin for an additional hour. MDM were then washed extensively with PBS and lysed with 0.1% Triton X-100 in PBS (or 0.5% saponin plus 2 mM EDTA for N. gonorrhoeae). Cell lysates were then serially diluted and plated for CFU enumeration.
Analysis of cytokine release. MDM were prepared as described above. Mid-log-phase bacteria (E. coli CFT073 and S. aureus UAMS-1) or N. gonorrhoeae swabbed into PBS from a GC agar plate were then mixed with PBS alone, monomeric PAP 248-286 peptide, SEVIala fibrils, or SEVI fibrils and added to the MDMs, as described for the phagocytosis assays. For this experiment, N. gonorrhoeae and E. coli were added to cells at 5 ϫ 10 5 cells/ml, and S. aureus at 5 ϫ 10 7 cells/ml (different concentrations of the organisms were used because of their distinct cell wall composition and differential ability to induce cytokine release). MDM were stimulated for 1 h with bacteria (with or without peptide/fibril) and then washed thoroughly, after which they were incubated for an additional 6 h. Cytokine levels in culture supernatants were then measured by enzyme-linked immunosorbent assay (ELISA).
N. gonorrhoeae infection model. Female BALB/c mice (Ͼ5 weeks old) were treated with water-soluble estradiol (Sigma) to promote susceptibility to N. gonorrhoeae infection as previously outlined (24, 25) . To prevent commensal bacterial overgrowth, mice were given streptomycin sulfate (0.24 mg intraperitoneally twice daily); note that the infecting N. gonorrhoeae strain FA1090 is streptomycin resistant (24, 25) . N. gonorrhoeae was swabbed into PBS from fresh GC agar plates and incubated for 30 min with or without SEVI (35 g/ml). Anesthetized mice were infected intravaginally with 10 6 CFU with or without SEVI (in a volume of 20 l), and infections were monitored by daily vaginal lavage with 30 l of PBS, serial diluting, and plating on GC agar.
RESULTS

SEVI binds to both Gram-negative and Gram-positive bacteria.
To test the binding of SEVI to bacteria, we incubated fluorescently labeled E. coli, S. aureus, and N. gonorrhoeae particles with biotinylated SEVI fibrils (22) or with matched but noncationic SEVIala fibrils. After incubation with the fluorescent bacteria, we captured the biotinylated fibrils (and any associated bacterial particles) onto antibiotin-conjugated MACS beads and quantitated the magnitude of captured bacterial fluorescence. Figure 1 shows that all 3 of the bacteria bound efficiently to the cationic SEVI fibrils but bound to the noncationic SEVIala fibrils at a level equivalent to the assay background level (i.e., binding to antibiotin beads in the absence of any fibril). Binding of bacteria to SEVI was between 3-and 10-fold greater than background binding (depending on the organism). In addition, the difference in binding to SEVI versus SEVIala achieved statistical significance for all of the organisms tested (Fig. 1) .
We next analyzed whether SEVI was capable of aggregating bacteria. Since the physiologic concentration of SEVI fibrils in semen is approximately 35 g/ml (3, 4), we performed these and subsequent experiments using concentrations of SEVI in this range. First, we vigorously mixed fluorescent bacterial particles in transparent glass vials, in the presence or absence of SEVI or SEVIala fibrils, and then incubated the tubes on the benchtop at room temperature for 1 h. As shown in Fig. 2A , the bacteria sedimented into a thick pellet at the bottom of the tube in the presence of SEVI fibrils only. To further examine the putative complexes formed between SEVI and bound bacteria, we performed TEM using SEVI fibrils that were incubated with S. aureus. The results, presented in Fig. 2B , show that the bacteria associated closely with the SEVI fibrils.
SEVI does not directly inhibit bacterial growth. Amyloidogenic peptides such as amyloid-␤ and protegrin-1 have been aureus (right) particles were vigorously mixed in PBS alone or in the presence of 40 g/ml of SEVI or SEVIala fibrils. Samples were then incubated at 37°C for 1 h and photographically imaged. The arrowheads denote sedimented bacterial aggregates. (B) S. aureus was incubated with SEVI (35 g/ml) for 1 h. Samples were fixed in 2.5% glutaraldehyde phosphate buffer, air dried, negatively stained on a carbon mesh grid, and imaged by transmission electron microscopy.
shown to possess direct antimicrobial activity (6-9). We therefore tested whether SEVI fibrils or monomeric PAP 248-286 peptide could also directly inhibit bacterial growth, using a panel of organisms known to be inhibited by the A␤42 peptide (8) . The results, shown in had no measurable effect on bacterial growtheven at concentrations as high as 128 g/ml.
SEVI facilitates phagocytosis of bacteria. We next examined the effect of SEVI on bacterial phagocytosis. To do this, we used killed bacterial particles labeled with the pH-sensitive fluorescent dye pHrodo (BioParticles; Invitrogen). pHrodo-labeled E. coli and S. aureus bacteria were mixed with SEVI or PBS alone and then added to MDM. SEVI-mediated aggregation of fluorescent bacterial particles resulted in a robust enhancement of phagocytosis when measured by flow cytometry (see Fig. S1 , upper panels, in the supplemental material). However, under control conditions, in which cells were pretreated with cytochalasin-D, there was significantly less fluorescence detected (see Fig. S1 , lower panels, in the supplemental material), confirming that uptake of the bacterial particles was mediated by phagocytosis (26) . This experiment was repeated multiple times using MDM from 3 to 5 different donors, and a summary of the results from these experiments is presented in Fig. 3 . Physiological levels of SEVI increased the percentage of MDM that phagocytosed bacterial particles from 28.7% to 49.0% of the cells for E. coli and from 53.5% to 78.4% of the cells for S. aureus (P ϭ 0.05 in both cases by the exact Wilcoxon rank sum test) (Fig. 3A and C) . SEVI also increased the median fluorescent intensity (MFI) of the positive cells, 2.3-fold for S. aureus and 1.39-fold for E. coli (P ϭ 0.05 in both cases by the exact Wilcoxon rank sum test) (Fig. 3B and D) . We speculate that the greater magnitude of SEVI's effect on the number of S. aureus particles taken up per cell may be related to the smaller size of S. aureus compared to E. coli (i.e., it is easier for a cell to ingest additional S. aureus particles). As noted above, when cells were preincubated with cytochalasin-D, the uptake of the particles was abolished (Fig. 3A and C) , confirming that the uptake detected was indeed phagocytic (26) . Finally, experiments using the monomeric PAP 248-286 peptide did not reveal any enhancement of bacterial phagocytosis (see Fig. S2 in the supplemental material), demonstrating that this effect is dependent upon fibrillization of the peptide.
To test whether SEVI also enhanced phagocytic uptake of live bacteria, we performed a gentamicin protection assay using the same strains of bacteria as those used to prepare the bioparticles. Mid-log-phase E. coli K-12, S. aureus Wood 46, or N. gonorrhoeae cells were preincubated with SEVI or PBS and then added to MDM or PMNs (in the case of N. gonorrhoeae). After 1 h, the inocula were removed and cells were treated with gentamicin in order to kill extracellular bacteria. MDMs or PMNs were then Comparison of the data presented in Fig. 3 and 4 reveals that SEVI-mediated enhancement of phagocytosis was greater for live than for killed S. aureus ( Fig. 3 and 4) . We tentatively attribute this to the fact that live S. aureus particles readily form short chains or clusters whereas killed particles do not.
We next tested whether the well-characterized staphylococcal virulence factor, protein A, might protect S. aureus against SEVImediated enhancement of phagocytosis, as it does against antibody-mediated enhancement of phagocytosis (27) . To do this, we took advantage of a spa-deleted mutant of the UAMS1 strain of S. aureus (KPL16) and its genetically complemented, protein A-positive counterpart (21) . As shown in Fig. 5 , SEVI-mediated enhancement of the phagocytosis of S. aureus was unaffected by the presence or absence of protein A.
SEVI enhances binding of bacteria to the surface of MDM. To test whether SEVI-mediated enhancement of bacterial phagocytosis might be secondary to increased binding of bacteria to MDM, we incubated FITC-labeled, killed bacterial particles with SEVI for 1 h and then added the fibril-particle mix to MDM that had been pretreated with cytochalasin-D to block phagocytosis. We found that SEVI enhanced E. coli binding to the surface of MDM over 10-fold (from an MFI of 57 to 677) and that it enhanced S. aureus binding over 5-fold (from an MFI of 1,270 to 6,480) (P ϭ 0.05 in both cases by the exact Wilcoxon rank sum test) (Fig. 6) . Control experiments showed that the monomeric PAP 248-286 peptide did not enhance bacterial binding to MDM (see Fig. S3 in the supplemental material) .
SEVI enhances bacterially mediated induction of cytokine release. In light of SEVI's ability to enhance bacterial binding and phagocytosis, we examined whether SEVI could increase bacterially induced release of cytokines by MDM. To do this, mid-logphase bacteria were incubated with SEVI for 1 h, and the fibrilparticle mixture was then added to MDM. After 1 h, the cells were washed thoroughly and then incubated for an additional 6 h to allow cytokine release. As shown in Fig. 7 , SEVI significantly enhanced proinflammatory cytokine release by MDM that were exposed to E. coli, S. aureus, or N. gonorrhoeae but had no effect on cytokine release in the absence of bacteria. SEVI increased TNF-␣ release from bacterially exposed MDM Ն2-fold for S. aureus, E. coli, and N. gonorrhoeae (from 2,970 pg/ml to 9,700 pg/ml for S. aureus, from 3,560 pg/ml to 11,900 pg/ml for E. coli, and from 5,420 pg/ml to 10,300 pg/ml for N. gonorrhoeae) (P Ͻ 0.0001 in all cases by the exact Wilcoxon rank sum test; Fig. 7 , left panel). SEVI had a similar effect on IL-6 release, increasing levels of this cytokine roughly 2-fold for S. aureus, E. coli, and N. gonorrhoeae (from 5,340 pg/ml to 9,190 pg/ml for S. aureus, from 4,310 pg/ml to 9,950 pg/ml for E. coli, and from 7,230 pg/ml to 12,400 pg/ml for N. gonorrhoeae) (P Ͻ 0.01 in all cases by the exact Wilcoxon rank sum test; Fig. 7, middle panel) . Finally, SEVI also stimulated IL-1␤ release from bacterially exposed MDM, raising levels of this cyto- kine by about 50% for S. aureus (from 180 to 306 pg/ml), almost 10-fold for E. coli (from 43 to 373 pg/ml), and about 5-fold for N. gonorrhoeae (from 40 to 198 pg/ml) (P ϭ 0.05 for S. aureus and P Ͻ 0.001 for E. coli and N. gonorrhoeae by the exact Wilcoxon rank sum test; Fig. 7, right panel) . The modest increase in IL-1␤ release from cells exposed to S. aureus (by about 50%) but strongly enhanced IL-1␤ release from cells exposed to N. gonorrhoeae and E. coli (5 to 10-fold) may be related to differences in the immunostimulatory activity of cell wall components of the bacteria.
SEVI inhibits vaginal colonization by N. gonorrhoeae. To examine the effects of SEVI on bacterial infection in vivo, we used N. gonorrhoeae as a representative sexually transmissible pathogen. We further took advantage of a well-described intravaginal infection model in BALB/c mice, in which N. gonorrhoeae infection can be reliably and reproducibly established in estradioltreated animals (24, 25) . Mice were intravaginally exposed to N. gonorrhoeae, in the presence or absence of SEVI. Infections were then monitored daily by vaginally lavaging mice with PBS, followed by enumeration of colony-forming bacteria. Animals that were intravaginally exposed to N. gonorrhoeae in the presence of SEVI were found to have consistently lower levels of bacterial infection, at both 1 and 3 days after experimental inoculation (Fig. 8 ). Animals exposed to N. gonorrhoeae plus SEVI had mean bacterial loads of 7.2 ϫ 10 4 (day 1) and 1.2 ϫ 10 4 (day 3), while animals exposed to N. gonorrhoeae in the absence of SEVI had mean bacterial loads that were 40-to 90-fold higher (2.9 ϫ 10 6 on day 1 and 1.1 ϫ 10 6 on day 3). These differences in bacterial load were statistically different at both time points (P Ͻ 0.05 by the Mann-Whitney test), suggesting that SEVI had a protective effect in vivo against vaginal colonization by N. gonorrhoeae.
DISCUSSION
While SEVI has been shown to greatly enhance HIV-1 infection in vitro, it currently has no known biological function. Based on the antimicrobial properties of other amyloidogenic peptides, we examined the antimicrobial activity of SEVI. At physiologic concentrations, SEVI had no direct inhibitory effect on bacterial growth in vitro (Table 1) . However, SEVI was found to efficiently bind to both Gram-positive (S. aureus) and Gram-negative bacteria (E. coli and N. gonorrhoeae) in a charge-dependent manner (Fig. 1) and to mediate their aggregation (Fig. 2) . This ability to aggregate bacteria is analogous to the recently described effects of other self-assembling host peptides, including ECP and human ␣-defensin 6, which can form "nanonets" that entrap bacterial pathogens (10, 11) . In addition, SEVI may also promote more-efficient binding of bacteria to mammalian cells (including macrophages; Fig. 4) , which is expected to be electrostatically unfavorable under normal conditions. This may result in sequestration of bacterial particles, favoring their subsequent clearance.
Overall, we attribute SEVI's ability to (i) enhance cellular uptake of bacteria, (ii) promote bacterially stimulated cytokine release, and (iii) protect against vaginal colonization by N. gonorrhoeae to its unique combination of cationic charge and fibrillar structure. Consistent with this, neither the monomeric PAP peptide nor the noncationic SEVIala fibril had any effect on bacterial phagocytosis or bacterially stimulated cytokine release.
In summary, SEVI is distinct from conventional antimicrobial peptides (28) and other bacterium-aggregating peptides, because it lacks direct antimicrobial activity and because its ability to enhance innate immune function is dependent on both its cationic charge and its fibrillar structure. We speculate that these structural properties may allow SEVI to bind to bacteria in a multivalent manner, allowing it to cross-link bacteria and to function as a "sticky mesh" capable of trapping microbial pathogens. Finally, the recent identification of other cationic amyloid fibrils in human semen (1-3) suggests that SEVI is not the only cationic amyloid fibril present in humans and that these fibrils may collectively represent a novel class of immune defense molecules. Future experiments are planned to address this hypothesis and to explore whether synthetic cationic amyloid fibrils (29) may also function as antibacterial agents and/or immune modulators.
